



HOIST Corporation

Representative chairman and CSO: Chihaya Kakinuma
Executive Officer, Head of Management Division, CFO: Koji Abe
(Representative phone number: 072-707-2760)

**HOIST Corporation announces a poster presentation at SOT 2025 regarding
HM-001, currently in clinical studies**

- HOIST Corporation presented an update of the HM-001 programme at SOT 2025, held in Orlando, Florida
- HM-001 is the lead programme of HOIST Corporation, and is currently in the Phase I portion of a Phase I/II clinical study
- HM-001 uses MA-T® technology, a revolutionary technology to control oxidation

Osaka, Japan – 21 Mar 2025 HOIST Corporation today announced that it has provided an update of the HM-001 programme which uses MA-T® technology, currently in Phase I clinical studies for non-muscle invasive bladder cancer (NMIBC).

The poster is entitled, “Development of HM-001 as a therapeutic drug for non-muscle invasive bladder cancer”. The abstract number is 3299.

Chihaya Kakinuma, the chairman of the company, said, “HM-001 is the lead compound for HOIST Corporation, and we look forward to continue progressing this programme for the benefit of bladder cancer patients. We believe that HM-001 represents a possibility of a new therapeutic option for patients with NMIBC.”

We shall be continuing to use our proprietary PDC/PDX technology to further our development programme that includes the HM-001 programme, currently in Phase I clinical studies.

About HOIST Corporation

Founded in 2019, HOIST Corporation is a clinical stage biotechnology company based in Osaka, Japan. Focusing on unmet needs in oncology, HOIST Corporation is exploring new approaches to cancer treatment.

About MA-T technology

MA-T® is an abbreviation of Matching Transformation System®, and is a revolutionary technology to control oxidation. By generating the required amount of activated species (water soluble radical) from sodium chlorite when necessary, it is possible to deactivate various virus (including epidemic virus) and bacteria. In addition, by controlling the activation, it may be possible to develop highly difficult chemical reactions, and



improve the functionality of polymers and applying them to devices, or applying to agricultural and medical uses. (taken from MA-T industrial association, <https://matjapan.jp/en/>)

About PDC/PDX Technology

Patient derived cells (PDC) and Patient derived xenografts (PDX) represent the next generation in cancer research, and allows for a model that more accurately mirrors the characteristics of the tumor compared with cancer cell lines.

Please refer to the following page regarding the details for our proprietary PDC/PDX technology:
<https://hoist-jp.com/en/home/technical-info/>

About HM-001

HM-001, the leading development candidate, is currently in Phase I/II clinical study. Pre-clinical studies which used HOIST's proprietary patient derived xenografts (PDX) showed therapeutic potential in non-muscle invasive bladder cancer (NMIBC).